Cost-effectiveness of Exercise Therapy in Patients with Intermittent Claudication: Supervised Exercise Therapy versus a 'Go Home and Walk' Advice

A. D. I. van Asselt, S. P. A. Nicolai, M. A. Joore, M. H. Prins, J. A. W. Teijink*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

46 Citations (Web of Science)


Objectives: The Exercise Therapy in Peripheral Arterial Disease (EXITPAD) study has shown supervised exercise therapy (SET) to be more effective regarding walking distance and quality of life than a 'go home and walk' advice (WA) for patients with intermittent claudication. The present study aims to assess the cost-effectiveness of SET versus WA. Patients and methods: Data from the EXITPAD study, a 12-month randomised controlled trial in 304 patients with claudication, was used to study the proportion of costs to walking distance and quality of life. Two different incremental cost-effectiveness ratios (ICERs) were calculated for SET versus WA: costs per extra metre on the treadmill test, and costs per quality-adjusted life year (QALY). QALYs were based on utilities derived from the EuroQoL-5 dimensions (EQ-5D). Results: Mean total costs were higher for SET than for WA (3407 versus 2304 Euros), mainly caused by the costs of exercise therapy. The median walking distance was 620 m for SET and 400 m for WA. QALYs were 0.71 for SET and 0.67 for WA. All differences were statistically significant. The ICER for cost per extra metre on the 12-month treadmill test was (sic) 4.08. For cost per QALY, the ICER was (sic) 28693. Conclusion: At a willingness-to-pay threshold of E 40 000 per QALY, SET likely is a cost-effective therapeutic option for patients with claudication.
Original languageEnglish
Pages (from-to)97-103
JournalEuropean Journal of Vascular and Endovascular Surgery
Issue number1
Publication statusPublished - Jan 2011


  • Intermittent claudication
  • Exercise therapy
  • Cost-effectiveness
  • Quality of life

Cite this